Quest Diagnostics Incorporated (DGX) Stock Forecast
Data as of Jul 31, 2026Healthcare · Current price $234.44 (+0.06%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 11, 2026 | Elizabeth Anderson | Evercore ISI | $220.00 | -6.2% |
| Feb 10, 2026 | Tycho Peterson | Jefferies | $220.00 | -6.2% |
| Oct 22, 2025 | Erin Wright | Morgan Stanley | $207.00 | -11.7% |
| Oct 17, 2025 | Kevin Caliendo | UBS | $190.00 | -19.0% |
| Jul 23, 2025 | Elizabeth Anderson | Evercore ISI | $185.00 | -21.1% |
| Apr 2, 2025 | Jamie Clark | Redburn Partners | $195.00 | -16.8% |
| Feb 3, 2025 | David Westenberg | Piper Sandler | $180.00 | -23.2% |
| Jan 31, 2025 | David MacDonald | Truist Financial | $182.00 | -22.4% |
| Jan 31, 2025 | Eric Coldwell | Robert W. Baird | $189.00 | -19.4% |
| Oct 23, 2024 | Patrick Donnelly | Citigroup | $185.00 | -21.1% |
| Oct 23, 2024 | Michael Cherny | Leerink Partners | $165.00 | -29.6% |
| Oct 23, 2024 | Stephanie Davis | Barclays | $168.00 | -28.3% |
| Oct 23, 2024 | Eric Coldwell | Robert W. Baird | $182.00 | -22.4% |
| Oct 22, 2024 | Paige Meyer | CFRA | $178.00 | -24.1% |
| Oct 7, 2024 | David MacDonald | Truist Financial | $165.00 | -29.6% |
| Jul 29, 2024 | Ann Hynes | Mizuho Securities | $160.00 | -31.8% |
| Jul 24, 2024 | Eric Coldwell | Robert W. Baird | $154.00 | -34.3% |
| Jul 15, 2024 | David MacDonald | Truist Financial | $158.00 | -32.6% |
| Apr 25, 2024 | Stephanie Davis | Barclays | $144.00 | -38.6% |
| Feb 7, 2024 | Brian Tanquilut | Jefferies | $155.00 | -33.9% |
Top Analysts Covering DGX
DGX vs Sector & Market
| Metric | DGX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.65 | 2.25 | 2.42 |
| Analyst Count | 17 | 8 | 19 |
| Target Upside | +3.2% | +16366.1% | +18.0% |
| P/E Ratio | 26.79 | 2.99 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $11.80B | $11.84B | $11.88B | 13 |
| 2027-03-31 | $2.95B | $2.99B | $3.04B | 5 |
| 2027-06-30 | $3.04B | $3.08B | $3.13B | 5 |
| 2027-09-30 | $3.07B | $3.11B | $3.16B | 5 |
| 2027-12-31 | $3.06B | $3.10B | $3.15B | 5 |
| 2028-03-31 | $3.09B | $3.13B | $3.18B | 4 |
| 2028-06-30 | $3.17B | $3.21B | $3.26B | 4 |
| 2028-09-30 | $3.19B | $3.23B | $3.29B | 4 |
| 2028-12-31 | $3.18B | $3.23B | $3.28B | 4 |
| 2029-12-31 | $13.42B | $13.55B | $13.73B | 5 |
| 2030-12-31 | $11.45B | $11.56B | $11.72B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $10.60 | $10.74 | $10.86 | 12 |
| 2027-03-31 | $2.65 | $2.70 | $2.75 | 4 |
| 2027-06-30 | $2.98 | $3.03 | $3.10 | 5 |
| 2027-09-30 | $2.96 | $3.02 | $3.08 | 8 |
| 2027-12-31 | $2.77 | $2.82 | $2.88 | 4 |
| 2028-03-31 | $2.93 | $2.99 | $3.05 | 5 |
| 2028-06-30 | $3.20 | $3.25 | $3.32 | 7 |
| 2028-09-30 | $3.20 | $3.26 | $3.33 | 10 |
| 2028-12-31 | $2.99 | $3.04 | $3.11 | 5 |
| 2029-12-31 | $13.81 | $13.97 | $14.23 | 6 |
| 2030-12-31 | $14.65 | $14.82 | $15.09 | 6 |
Frequently Asked Questions
What is the analyst consensus for DGX?
The consensus among 17 analysts covering Quest Diagnostics Incorporated (DGX) is Hold with an average price target of $220.57.
What is the highest price target for DGX?
The highest price target for DGX is $220.00, set by Elizabeth Anderson at Evercore ISI on 2026-02-11.
What is the lowest price target for DGX?
The lowest price target for DGX is $144.00, set by Stephanie Davis at Barclays on 2024-04-25.
How many analysts cover DGX?
17 analysts have issued ratings for Quest Diagnostics Incorporated in the past 12 months.
Is DGX a buy or sell right now?
Based on 17 analyst ratings, DGX has a consensus rating of Hold (2.65/5) with a +3.2% upside to the consensus target of $220.57.
What are the earnings estimates for DGX?
Analysts estimate DGX will report EPS of $10.74 for the period ending 2026-12-31, with revenue estimated at $11.84B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.